Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies

BACKGROUND: The clinical trials that reported benefit of the rapalogs temsirolimus and everolimus in advanced renal cell carcinoma (RCC) were primarily conducted in patients with clear-cell histology (ccRCC). We assessed outcome with these mammalian target of rapamicin (mTOR) inhibitors in two subse...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Ann Oncol
Huvudupphovsmän: Voss, M. H., Bastos, D. A., Karlo, C. A., Ajeti, A., Hakimi, A. A., Feldman, D. R., Hsieh, J. J., Molina, A. M., Patil, S., Motzer, R. J.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Oxford University Press 2014
Ämnen:
Original Articles
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4229900/
https://ncbi.nlm.nih.gov/pubmed/24458473
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdt578
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk